HN2005000548A - Procedimiento para producir derivados de amina opticamente activos - Google Patents

Procedimiento para producir derivados de amina opticamente activos

Info

Publication number
HN2005000548A
HN2005000548A HN2005000548A HN2005000548A HN2005000548A HN 2005000548 A HN2005000548 A HN 2005000548A HN 2005000548 A HN2005000548 A HN 2005000548A HN 2005000548 A HN2005000548 A HN 2005000548A HN 2005000548 A HN2005000548 A HN 2005000548A
Authority
HN
Honduras
Prior art keywords
procedure
optically active
derivatives
reaction
amina
Prior art date
Application number
HN2005000548A
Other languages
English (en)
Inventor
Urayama Shinichi
Sugisaki Shigeharu
Mutou Eigo
Inagaki Atsushi
Okada Takashi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36059992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2005000548(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of HN2005000548A publication Critical patent/HN2005000548A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)

Abstract

SE PROVEE UN PROCEDIMIENTO INDUSTRIAL PARA PRODUCIR LOS DERIVADOS DE AMINA OPTICAMENTE ACTIVOS DE ELEVADA PUREZA, EN DONDE ES CONTROLADA LA FORMACION DE PRODUCTOS COLATERALES. EN DICHO PROCEDIMIENTO, LA (E)-2(1,6,7,8-TETRAHIDRO-2H-INDENO[5,4-B]FURAN-8-ILIDEN)ETILAMINA ES SOMETIDA A LA REACCION DE REDUCCION ASIMETRICA, Y ADEMAS LOS PRODUCTOS DE REACCION RESULTANTES SON REDUCIDOS CATALITICAMENTE BAJO UNA CONDICION DE TEMPERATURA DE REACCION DE REDUCCION ASIMETRICA, Y ADEMAS LOS PRODUCTOS DE REACCION RESULTANTES SON REDUCIDOS CATALITICAMENTE BAJO UNA CONDICION DE TEMPERATURA DE RACCION DE 40 GRADOS CENTIGRADOS A 100 GRADOS CENTIGRADOS Y PH DE 3 A 9, ENTONCES LA (S)-2- (1,6,7,8,-TETRAHIDRO-2H-INDENO[5,4-B]FURAN-8-IL)ETILAMINA OBTENIDA ES SOMETIDA A REACCION DE PROPIONILACION, SEGUIDO DE CRISTALIZACION DE LA SOLUCION DE REACCION.
HN2005000548A 2004-09-13 2005-09-13 Procedimiento para producir derivados de amina opticamente activos HN2005000548A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004265307 2004-09-13

Publications (1)

Publication Number Publication Date
HN2005000548A true HN2005000548A (es) 2007-04-20

Family

ID=36059992

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2005000548A HN2005000548A (es) 2004-09-13 2005-09-13 Procedimiento para producir derivados de amina opticamente activos

Country Status (31)

Country Link
US (4) US8097737B2 (es)
EP (2) EP1792899B1 (es)
JP (2) JP5127228B2 (es)
KR (1) KR101298335B1 (es)
CN (2) CN102516211A (es)
AR (1) AR050737A1 (es)
AU (1) AU2005283521B2 (es)
BR (1) BRPI0515170A (es)
CA (2) CA2764314C (es)
CR (2) CR8975A (es)
EC (1) ECSP077317A (es)
ES (1) ES2485890T3 (es)
GE (1) GEP20094725B (es)
GT (2) GT200500257AA (es)
HN (1) HN2005000548A (es)
IL (2) IL181462A (es)
MA (1) MA28855B1 (es)
MX (1) MX2007002822A (es)
MY (2) MY147822A (es)
NO (1) NO20071866L (es)
NZ (1) NZ553562A (es)
PA (1) PA8645701A1 (es)
PE (3) PE20081390A1 (es)
RU (1) RU2385318C2 (es)
SA (1) SA05260347A (es)
SG (1) SG151330A1 (es)
TW (1) TWI400220B (es)
UA (1) UA95598C2 (es)
UY (1) UY29118A1 (es)
WO (1) WO2006030739A1 (es)
ZA (1) ZA200701724B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008123067A1 (ja) * 2007-03-19 2008-10-16 Takeda Pharmaceutical Company Limited アリルアミン不斉水素化法
WO2008150953A1 (en) * 2007-05-30 2008-12-11 Dr. Reddy's Laboratories Ltd. Process of making ramelteon and related substances
US8084630B2 (en) 2007-05-31 2011-12-27 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
WO2009060318A2 (en) * 2007-07-12 2009-05-14 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ramelteon and processes for preparation thereof
CN101531647B (zh) * 2008-03-13 2012-10-31 常州亚邦制药有限公司 (±)-2-(1,6,7,8-四氢-2H-茚并[5,4-b]呋喃-8-基)乙胺的拆分方法
JP2011528012A (ja) * 2008-07-14 2011-11-10 レツク・フアーマシユーテイカルズ・デー・デー ラメルテオンの調製における中間体としての６，７−ジヒドロ−１ｈ−インデノ［５，４−ｂ］フラン−８（２ｈ）−オンの合成
WO2010045565A1 (en) * 2008-10-16 2010-04-22 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
US20120071673A1 (en) 2009-02-12 2012-03-22 Lek Pharmaceuticals D.D. Synthesis of (s)-n-[2-(1,6,7,8-tetrahydro-2h-indeno-[5,4-b]furan-8-yl)ethyl]propionamide
CN101824012B (zh) * 2009-03-02 2011-12-07 四川大学 2-(1,6,7,8-四氢-2H-茚并-[5,4-b]呋喃-8-基)乙腈及其制备方法和用途
EP2406242B1 (en) 2009-03-10 2013-06-05 Industriale Chimica S.R.L. Process for the preparation of ramelteon
EP2243775A1 (en) 2009-04-07 2010-10-27 LEK Pharmaceuticals d.d. Synthesis of 1-(2,3-Dihydrobenzofuran-4-YL)ethanone as intermediate in the preparation of ramelteon
WO2011027323A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Process for the preparation of ramelteon
WO2011027319A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Process for the preparation of an intermediate for ramelteon
CN101648931B (zh) * 2009-09-21 2012-05-09 四川大学 一种3-(2,3-二氢苯并呋喃-5-基)-丙酸的制备方法
CN101665477B (zh) * 2009-09-21 2012-05-09 四川大学 (e)-3-(苯并呋喃-5-基)丙烯酸酯类化合物、其制备方法和用途
EP2483258A1 (en) 2009-09-29 2012-08-08 Lonza Ltd. Process for preparing 1,2,6,7-tetrahydro-8h-indeno[5,4-b]furan-8-one
WO2012035303A2 (en) 2010-09-17 2012-03-22 Cipla Limited Et Al A novel process for synthesis of ramelteon, and key intermediates for the synthesis of ramelteon
CN103664849B (zh) * 2012-08-31 2017-03-29 上海阳帆医药科技有限公司 制备2‑(1,6,7,8‑四氢‑2H‑茚并[5,4‑b]呋喃‑8‑亚基乙胺的方法
CN102924410A (zh) * 2012-10-29 2013-02-13 华润赛科药业有限责任公司 一种雷美替胺的制备方法及其中间体
CN103396387A (zh) * 2013-08-07 2013-11-20 安徽联创药物化学有限公司 雷美替胺中间体的制备方法
CN105277628B (zh) * 2014-07-07 2017-05-31 南京长澳医药科技有限公司 通过高效液相色谱法分离测定雷美替胺及其杂质的方法
CN104402848B (zh) * 2014-09-22 2017-02-08 珠海联邦制药股份有限公司 雷美替胺中的杂质化合物的制备方法及制备的标准品
CN105622557B (zh) * 2014-11-05 2018-12-04 上海医药工业研究院 雷美替胺中间体及其制备方法
KR102359229B1 (ko) 2020-04-16 2022-02-07 제이투에이치바이오텍 (주) 라멜테온의 제조 방법 및 이러한 제조 방법에 이용되는 중간체 화합물
CN115477628A (zh) * 2022-10-17 2022-12-16 江苏海悦康医药科技有限公司 一种雷美替胺二聚体的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0757758B2 (ja) 1988-10-24 1995-06-21 高砂香料工業株式会社 ルテニウム―ホスフィン錯体
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
CN1066725C (zh) 1995-03-02 2001-06-06 三共株式会社 旋光性噻唑烷酮衍生物
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
EP1199304A1 (en) * 1997-03-05 2002-04-24 Takeda Chemical Industries, Ltd. Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders
JP4242940B2 (ja) 1997-02-13 2009-03-25 高砂香料工業株式会社 光学活性アミン誘導体の製造法
JP4081161B2 (ja) * 1997-09-05 2008-04-23 武田薬品工業株式会社 光学活性化合物の製造法
DE69910795T2 (de) * 1998-06-09 2004-06-17 Takeda Chemical Industries, Ltd. Pharmazeutische kombination mit einer trizyclischen verbindung und mindestens einer von zolpidem, zopiclone und brotizolam, zur behandlung oder verhinderung von schlafstörungen
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
DE60142305D1 (de) * 2000-11-17 2010-07-15 Takeda Pharmaceutical Pharmazeutische zubereitung enthaltend n-ä2-(1,6,7,8-tetrahydro-2h-indenoä5,4 büfuran-8-yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung
JP3633895B2 (ja) 2000-11-17 2005-03-30 武田薬品工業株式会社 コポリビドン含有製剤

Also Published As

Publication number Publication date
CR20110698A (es) 2012-03-08
GT200500257A (es) 2006-04-17
CA2579121C (en) 2013-07-30
WO2006030739A1 (ja) 2006-03-23
GT200500257AA (es) 2008-07-28
GEP20094725B (en) 2009-07-10
PE20060662A1 (es) 2006-08-22
CN101056867A (zh) 2007-10-17
SA05260347A (ar) 2005-12-03
US8097737B2 (en) 2012-01-17
US20130079397A1 (en) 2013-03-28
RU2007113811A (ru) 2008-10-20
KR20070054200A (ko) 2007-05-28
SG151330A1 (en) 2009-04-30
TWI400220B (zh) 2013-07-01
US20090036521A1 (en) 2009-02-05
NO20071866L (no) 2007-05-29
TW200613239A (en) 2006-05-01
MX2007002822A (es) 2007-04-23
EP2537842A1 (en) 2012-12-26
AU2005283521B2 (en) 2011-10-13
EP1792899A1 (en) 2007-06-06
CA2764314C (en) 2014-06-17
EP1792899A4 (en) 2009-12-16
JP5615304B2 (ja) 2014-10-29
PA8645701A1 (es) 2006-09-22
PE20081390A1 (es) 2008-10-24
IL207510A (en) 2013-02-28
UA95598C2 (ru) 2011-08-25
ES2485890T3 (es) 2014-08-14
EP1792899B1 (en) 2014-07-09
IL181462A (en) 2011-12-29
KR101298335B1 (ko) 2013-08-20
JPWO2006030739A1 (ja) 2008-05-15
MA28855B1 (fr) 2007-09-03
RU2385318C2 (ru) 2010-03-27
IL181462A0 (en) 2007-07-04
JP5127228B2 (ja) 2013-01-23
MY158073A (en) 2016-08-30
CN102516211A (zh) 2012-06-27
CA2764314A1 (en) 2006-03-23
PE20130154A1 (es) 2013-02-27
ZA200701724B (en) 2008-08-27
CA2579121A1 (en) 2006-03-23
US20140066499A1 (en) 2014-03-06
US8609871B2 (en) 2013-12-17
ECSP077317A (es) 2007-04-26
MY147822A (en) 2013-01-31
JP2012116848A (ja) 2012-06-21
AU2005283521A1 (en) 2006-03-23
AR050737A1 (es) 2006-11-15
CN101056867B (zh) 2011-12-07
BRPI0515170A (pt) 2008-07-08
CR8975A (es) 2007-08-28
US20120088826A1 (en) 2012-04-12
NZ553562A (en) 2010-08-27
UY29118A1 (es) 2006-06-30

Similar Documents

Publication Publication Date Title
HN2005000548A (es) Procedimiento para producir derivados de amina opticamente activos
EA200300211A1 (ru) Азабициклические соединения, способ их получения и их применение в качестве лекарственных средств, в частности в качестве антибактериальных средств
SE0002102D0 (sv) Chemical compound
UY26841A1 (es) Sales estables de ácido o-acetilsalicílico con aminoácidos básicos
CY1107875T1 (el) Παραγωγα αμινοκινολινης και η χρηση τους ως συνδετες των α3 αδενοσινης
IL178032A0 (en) An improved process for the preparation of n-([1,2,4-]triazolopyrimidin-2-yl)aryl sulfonamides
DK1594885T3 (da) Lægemiddel til vækstinhibering af tumorer
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
NO20060497L (no) Fremstilling av metalsalter av fettsyrer med middels kjedelengde
BR0212542A (pt) Método para a preparação de gluconato de cálcio, e, mistura de sal de glucomato/sal de ácido orgânico
CY1111960T1 (el) Νεα φαρμακευτικα παρασκευασματα καθως επισης μεθοδος για την παρασκευη αυτων
CY1112714T1 (el) Διαδικασια για την παρασκευη υψηλης-καθαροτητας μελοξικαμης και αλατος καλιου της μελοξικαμης
ECSP003680A (es) Proceso para derivados del acido fenilacetico
PT1165485E (pt) Processo para a preparacao de produtos intermediarios pesticidas
PT1289930E (pt) Processo para produzir acido 5-aminosalicilico
ES2076166T3 (es) Procedimiento para producir 2-amino-4,6-dicloropirimidina.
AR051933A1 (es) Proceso para la preparacion de n-(3,5 dicloropirid-4-ilo)-4-difluormetoxi-8-metano sulfonamido-dibenzo[b,d] furano-1-carboxamida
PT1252164E (pt) Processo para a preparacao de acido 6-(4-clorofenil)-2,2-dimetil-7-fenil-2,3-dihidro-1h-pirrolizin-5-il acetico
PT1861352E (pt) Processo para a preparação de derivados de ácido 3- fenilpropiónico opticamente activos e respectivos produtos secundários
BR0214171A (pt) Processo para a hidrogenação de acetona para a preparação de isopropanol
PE20011181A1 (es) (5R)-(METILAMINO)-5,6-DIHIDRO-4H-IMIDAZO[4,5,1-ij]QUINOLIN-2(1H)-TIONA
ES2194745T3 (es) Procedimiento para la obtencion de 4,6-dicloropirimidi-na.
BRPI0409644A (pt) processo para a preparação de nicotinaldeìdos
ATE479649T1 (de) Zwischenprodukte und verfahren zur herstellung aromatischer derivate von 1-adamantan
TH81175A (th) กระบวนการสำหรับการผลิตอนุพันธ์แอมีนทำปฏิกิริยาเชิงแสง